HCW Biologics Inc. cotiza a 1.26 USD y tiene una capitalización bursátil de $3M. En los últimos 12 meses ha facturado $7M con un margen de flujo de caja libre del -24693.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule tha…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $2.22 | $-6.12 | $-12.12 | $-40.74 |
| Estimado | $-2.64 | $-5.04 | $9.48 | $10.80 |
| Sorpresa | +184.1% | -21.4% | -227.8% | -477.2% |
| Métrica | HCWB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 20.0% | 57.0% | -37.0% |
| Operating Margin | -24270.7% | -38.6% | -24232.1% |
| Net Margin | -14677.1% | -33.6% | -14643.6% |
| FCF Margin | -24693.2% | -13.9% | -24679.3% |
| ROE | -287.9% | -40.4% | -247.5% |
| ROA | -32.5% | -32.0% | -0.5% |
| Current Ratio | 0.11 | 2.84 | -2.73 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |